Clinical trials: Hypervascular Tumors
Vascular Anomalies, Hemorrhage
Safety and Efficacy Of Amber Peripheral Liquid Embolic System
A prospective, single-arm, multicenter, open-label, First-in-Human \& Pivotal Study to assess the safety and efficacy of amber SEL-P in 70 patients requiring peripheral embolization: vascular anomalies, hemorrhages, aneurysms…
- Conditions
- Vascular Anomalies, Hemorrhage, Aneurysm, Pseudoaneurysm
- Trial name
- OPAL (NCT06456125)
- Testing
- amber SEL-P Peripheral Liquid Embolic System
- Where
- Spain
- Volunteers
- 70 people
- Sponsor
- LVD Biotech S.L
Hepatocellular Carcinoma, Neuroendocrine Tumors
Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery
The goal of this clinical trial is to compare CT scan of the coverage of tumors treated with TACE using End Hole catheters to those treated with the TriNav catheter that alters tissue pressure.
- Trial name
- Trinav (NCT06204159)
- Testing
- TACE Catheters
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Soft Tissue Sarcomas
Phase I Study of Safety and Feasibility of Transarterial Embolization of Incurable Hypervascular Pediatric Soft Tissue Sarcomas
This is a single center, single arm phase I clinical trial exploring the feasibility and safety of performing transarterial embolization of incurable hypervascular pediatric soft tissue sarcomas with at least an index tumor with…
- Trial name
- NCT07136571
- Testing
- bland particles
- Sponsor
- University of Alabama at Birmingham
Hypervascular Tumor and Arteriovenous Malformation
A Multicenter, Open-label Study for E7040 in Japanese Subjects With Hypervascular Tumor and Subjects With Arteriovenous Malformation
To evaluate the efficacy and safety of transcatheter arterial embolization with E7040 in Japanese subjects with hypervascular tumor or arteriovenous malformation
- Trial name
- NCT01677624
- Testing
- E7040
- Where
- 10 sites in Japan
- Volunteers
- 28 people
- Sponsor
- Eisai Co., Ltd.
Hypervascular Tumors, Bleeding
Obsidio™ Conformable Embolic Registry
OCCLUDE is a prospective, post-approval, open-label, single arm, multi-center US registry of patients who undergo embolization with Obsidio™ Conformable Embolic.
- Conditions
- Hypervascular Tumors, Bleeding, Hemorrhage
- Trial name
- OCCLUDE (NCT06170619)
- Testing
- Obsidio™ Conformable Embolic
- Where
- 20 sites in United States
- Volunteers
- 125 people
- Sponsor
- Boston Scientific Corporation
Hypervascular Tumors
Instylla HES Hypervascular Tumor Pivotal Study
To determine whether Instylla HES has the ability to effectively embolize targeted arterial segments of hypervascular tumors as well as (i.e., is non-inferior to) standard of care (SOC) transarterial embolization/conventional…
- Trial name
- NCT04523350
- Testing
- Instylla HES, TAE or cTACE
- Where
- 15 sites in United States, Canada
- Volunteers
- 150 people
- Sponsor
- Instylla, Inc.
Malignant Neoplasm in the Head and Neck, Metastatic Malignant Neoplasm in the Head and Neck
Preoperative Embolization of Hypervascular Head and Neck Tumors to Improve Surgical Outcomes
This phase I trial tests whether embolization done prior to surgery (preoperative) will improve surgical outcomes in head and neck tumors with large amounts of blood vessels (hypervascular).
- Trial name
- NCT05490381
- Testing
- Iodixanol, Angiogram, Arterial Embolization
- Where
- United States
- Sponsor
- University of Washington
Uterine Fibroid, Arteriovenous Malformations
An Observational Study of Radial Access Embolization Procedures Using HydroPearl Microspheres
This registry study is designed to collect data on the procedural success and complication rates in real-world patients undergoing HydroPearl embolization procedures via radial access.
- Conditions
- Uterine Fibroid, Arteriovenous Malformations, Hypervascular Tumors, Benign Prostatic Hyperplasia
- Trial name
- RAVI Registry (NCT04272216)
- Testing
- Treatment with HydroPearl via radial access
- Where
- 6 sites in United States
- Volunteers
- 99 people
- Sponsor
- Terumo Medical Corporation